抗肿瘤血管形成的治疗新模式——节拍器化疗联合放射治疗  

A New Treatment Protocol Targeting Tumor Vasculature——Metronomic Chemotherapy Combined Radiotherapy

作　　者：邱灏[1] 王国民[1] 

机构地区：[1]上海华东医院放疗科,上海200040

出　　处：《癌症》2007年第12期1392-1396,共5页Chinese Journal of Cancer

摘　　要：肿瘤生长、转移有赖于其血管生成,故抗肿瘤血管治疗被认为是一种很有前途的肿瘤治疗靶点。研究发现经典化疗药物如环磷酰胺、甲氨蝶呤、紫杉醇等在长期、低剂量的非常规给药方式(节拍器化疗)下具有显著的抗肿瘤血管生成能力。另一方面,肿瘤的血供、乏氧状况是决定放射治疗(放疗)疗效的重要因子。抗血管靶向治疗在实验室和临床早期试验中均表现出放疗增敏作用。本文综述了节拍器化疗和放疗的抗肿瘤血管机理和临床初步应用结果,提出放疗与节拍器化疗联合治疗,可能克服肿瘤乏氧诱发的放射抗拒,最终提高放疗的疗效,有望成为一种全新的治疗模式。Tumor growth and metastasis depend on its angiogenesis ability. The anti-angiogenic treatment is considered as a hopeful treatment for tumors. The anti-angiogenic efficacy of classic cytotoxic agents, such as cyclophosphomide, methotraxate, taxol, and so on, could be enhanced by changing the dose delivering schedule, naming ＂metronomic chemotherapy＂. Additionally, tumor vasculature and hypoxic status are important predictive factors for the efficacy of radiotherapy. Furthermore, the anti-angiogenic treatment can enhance the irradiation sensitivity of tumors. This review have summarized the anti-angiogenic mechanism of metronomic chemotherapy combined radiotherapy and the preliminary applications in clinic and proposed that the combination of radiotherapy and metronomic chemotherapy can overcome the hypoxia-related radioresistance and increase the efficacy of radiotherapy.

关 键 词：节拍器化疗 放射治疗 联合疗法 抗血管形成 治疗模式 

分 类 号：R730.5[医药卫生—肿瘤]